

In re: Patent application of Keith R. McCrae  
Attorney Docket No.: 6056-260; 35926-147539  
Serial No.: 09/461,061

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

DL 1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound consisting of the formula  $X_1$ -SEQ ID NO:1- $X_2$  wherein

$X_1$  is from zero to twelve amino acids, and

$X_2$  is from zero to twelve amino acids.

2. (Original) The composition of Claim 1, wherein

$X_1$  is from zero to six amino acids, and

$X_2$  is from zero to six amino acids.

3. (Original) The composition of claim 1 wherein

$X_1$  is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

$X_2$  is

(i) zero amino acids, or

40

D

*In re*: Patent application of Keith R. McCrae  
Attorney Docket No.: 6056-260; 35926-147539  
Serial No.:09/461,061

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.

01  
cont.

4. (Original) The composition of claim 1 wherein the compound has substantial amino acid sequence homology to the amino acid sequence SEQ ID NO:4.

5. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:1.

6. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:9.

7. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:10.

8 Cancelled

9. Cancelled

10. Cancelled

11. Cancelled

12. Cancelled

13. Cancelled

14. Cancelled

389095 v2/DC

4 -

41

D

*In re:* Patent application of Keith R. McCrae  
Attorney Docket No.: 6056-260; 35926-147539  
Serial No.: 09/461,061

15. Cancelled

16. Cancelled

17. Cancelled

18. Cancelled

19. Cancelled

20. Cancelled

21. Cancelled

22. Cancelled

23. Cancelled

8 24. (Original) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a composition according to claim 1.

25. Cancelled

26. Cancelled

27. Cancelled

42

P

*In re:* Patent application of Keith R. McCrae  
Attorney Docket No.: 6056-260; 35926-147539  
Serial No.: 09/461,061

28. Cancelled

29. Cancelled

30. Cancelled

31. Cancelled

32. Cancelled

33. Cancelled

34. Cancelled

35. Cancelled

36. Cancelled

37. Cancelled

38. Cancelled

39. Cancelled

40. Cancelled

41. Cancelled



In re: Patent application of Keith R. McCrac  
Attorney Docket No.: 6056-260; 35926-147539  
Serial No.: 09/461,061

42. Cancelled

43. Cancelled

44. Cancelled

45. Cancelled

46. Cancelled

47. Cancelled

48. Cancelled

9  
~~49.~~ (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 2.

10  
~~50.~~ (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 3.

11  
~~51.~~ (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 4.

12  
~~52.~~ (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 5.

13  
~~53.~~ (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 6.

In re: Patent application of Keith R. McCrae  
Attorney Docket No.: 6056-260; 35926-147539  
Serial No.:09/461,061

14  
54. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 7.

15  
55. (Previously presented) A method for inhibiting angiogenesis comprising administering to a mammal an effective amount of a compound of the formula  $X_1$ -SEQ ID NO:1- $X_2$  wherein

*Q1 conclude*  
16  
 $X_1$  is from zero to twelve amino acids, and

$X_2$  is from zero to twelve amino acids.

56. (Previously presented) A method of inhibiting angiogenesis according to claim 1 wherein

$X_1$  is

- (i) zero amino acids, or
- (ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

$X_2$  is

- (i) zero amino acids, or
- (ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.

*44**D*